Applies to most patients with one or two positive sentinel lymph nodes ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting ...

Thousands of women could now be spared one of the most debilitating side-effects of breast cancer treatment - lifelong ...